AGGF1 Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population in the HEK293T cell line, generated by targeted disruption of the AGGF1 gene. This heterogeneous pool captures a range of loss-of-function alleles introduced by CRISPR/Cas9-mediated gene editing, providing a robust model for investigating AGGF1 function without the artifacts associated with clonal selection. The polyclonal format supports bulk biochemical and cellular assays, ensuring broad representation of knockout variants in downstream applications.
HEK293T is a human embryonic kidney epithelial cell line derived from the parental HEK293 line, which was originally transformed with sheared adenovirus 5 DNA. The cells stably express the SV40 large T antigen, enabling episomal replication of plasmids containing the SV40 origin of replication. Renowned for their high transfectability and efficient protein expression, HEK293T cells are a mainstay in molecular biology for recombinant protein production, viral packaging, and functional genomics studies.
AGGF1 encodes a secreted angiogenic factor that plays a central role in vascular development by activating endothelial cell proliferation, migration, and tube formation. The protein interacts directly with VEGFR2 and HDAC7, and its expression is regulated by upstream signals including HIF-1??, TWEAK, and TNF??. Downstream, AGGF1 stimulates the PI3K/AKT and ERK1/2 pathways, leading to mTOR and S6K activation, as well as eNOS phosphorylation, thereby coordinating angiogenic and metabolic responses.
Although HEK293T cells lack an endothelial phenotype, this knockout pool enables biochemical dissection of AGGF1 signaling in a simplified epithelial context. The cells are particularly suited for mapping AGGF1 protein interactions??for instance, co-immunoprecipitation with HDAC7??and for reconstituting pathway activation via transient or stable AGGF1 expression. Phosphorylation of AKT and ERK1/2 can be readily monitored by Western blotting, while transcriptional changes in angiogenic targets can be profiled by RT-qPCR, decoupling AGGF1??s molecular functions from endothelial-specific processes.
This product is ideal for applications in angiogenesis research, cancer biology, and ischemic disease modeling. It supports drug screening for modulators of AGGF1-dependent signaling, immunofluorescence localization of interacting partners, and high-throughput assays such as flow cytometry-based phospho-signaling measurements. The polyclonal pool also enables ELISA-based detection of secreted factors and co-culture studies to assess paracrine effects. These cells provide a reliable loss-of-function platform for mechanistic investigations and therapeutic targeting of AGGF1. For further details, please contact Ascent Research.
